Seqirus Announces FDA Approval of Its First-Ever Adjuvanted, Cell-Based Pandemic Influenza A (H5N1)…
Seqirus announced that the U.S. Food and Drug Administration (FDA) has approved AUDENZ (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) to help protect individuals six months of age…
Read More...
Read More...
